Amicus Therapeutics (FOLD) Tops Q1 EPS by 5c, Misses on Revenue
Tweet
Share
E-mail
Get Alerts FOLD Hot Sheet
Price: $14.49 --0%
Financial Fact:
Interest expense: -1.52M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Financial Fact:
Interest expense: -1.52M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
(Updated - May 1, 2025 10:00 AM EDT)
Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of $0.03, $0.05 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $125.25 million versus the consensus estimate of $136.65 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
- BMO Capital Upgrades Incyte (INCY) to Market Perform
- Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
